Risk of Local Adverse Events following Cardiac Catheterization by Hemostasis Device Use - Phase II
Note: This article is available on an external website. You are now leaving the U.S. Food and Drug Administration website.
Links to any non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by the FDA or the Federal Government, and none should be inferred. Any reference to a commercial product, process, service, or company is not an endorsement or recommendation by the U.S. government, the Department of Health and Human Services, FDA or any of its components. The FDA is not responsible for the content of the individual organization Web pages found at these links.